Login
Intercept Pharmaceuticals NASDAQ: ICPT
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases
| Name | Intercept Pharmaceuticals |
| Ticker | ICPT |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
20.55
19.33 / 92.04 |
| Momentum | Neutral |
| Market cap | 678 M |
| 1Y Total Return |
-72.47%
Weak |
| 1Y Volatility |
88.37%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases
Details
| Ticker | ICPT |
| Name | Intercept Pharmaceuticals |
| ISIN | US45845P1084 |
| CUSIP | 45845P108 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/15/21
| Close Price | 20.55 |
| 52W Low/High | 19.33 / 92.04 |
| Market cap | 678 M |
| 1Y Total Return |
-72.47%
Weak |
| 1Y Volatility |
88.37%
High Risk |
| Beta | 2.14 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -87.9% |
| Cash from Op. / Cur. Liabilities | -0.95 |
| Diluted Earnings / Share | -8.34 |
| ROE | - |
| ROIC | -53.1% |
| Price / Revenue | 2.2 |
| Price / Book | -4.1 |
| Price / CF | -4.0 |
| Current Ratio | 3.0 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
313
|
252
|
180
|
131
|
25
|
3
|
|
| Gross Profit |
307
|
248
|
177
|
130
|
25
|
3
|
|
| R&D |
191
|
243
|
207
|
191
|
154
|
113
|
|
| EBITDA |
-218
|
-294
|
-274
|
-326
|
-395
|
-225
|
|
| Operating Income |
-231
|
-312
|
-285
|
-336
|
-403
|
-229
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
33
|
32
|
28
|
25
|
25
|
24
|
|
| EPS exc. Extra |
-8.34
|
-10.89
|
-10.86
|
-14.38
|
-16.74
|
-9.56
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
580
|
755
|
509
|
484
|
739
|
656
|
|
| Cash, Eq & Invt ShortTerm |
477
|
657
|
436
|
415
|
689
|
628
|
|
| Total Current Assets |
546
|
721
|
482
|
448
|
708
|
642
|
|
| Total Non-Current Assets |
35
|
34
|
27
|
36
|
31
|
14
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
747
|
703
|
490
|
468
|
424
|
54
|
|
| Total Current Liabilities |
179
|
162
|
114
|
104
|
79
|
47
|
|
| Long Term Debt |
568
|
541
|
376
|
364
|
346
|
6
|
|
| Shareholder equity |
-167
|
52
|
19
|
16
|
315
|
602
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-170
|
-237
|
-241
|
-265
|
-342
|
-163
|
|
| Depreciation |
9
|
9
|
5
|
5
|
4
|
2
|
|
| Cash from Investing |
163
|
-189
|
-48
|
288
|
-60
|
-389
|
|
| Capex |
4
|
1
|
0
|
10
|
5
|
6
|
|
| Cash from Financing |
-1
|
458
|
264
|
3
|
414
|
565
|
|
| Stock Issued |
1
|
236
|
266
|
3
|
5
|
565
|
|
| Debt (LT) Issued |
0
|
223
|
0
|
0
|
448
|
0
|
|
| Free Cash Flow |
362
|
-466
|
-335
|
-40
|
-435
|
-574
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
3.0
|
4.5
|
4.2
|
4.3
|
9.0
|
13.5
|
|
| Financial Leverage D/E |
-
|
10.32
|
19.41
|
21.71
|
1.08
|
0.00
|
|
| Return on Capital Avg |
-53.1%
|
-69.8%
|
-84.2%
|
-71.4%
|
-66.8%
|
-57.0%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available